NEW YORK (GenomeWeb) — Personal Genome Diagnostics announced today that its non-invasive pan-cancer plasma assay will be used in a clinical trial evaluating Bristol-Myers Squibb's cancer drugs Opdivo (nivolumab) and Yervoy (ipilimumab) in patients with specific genetic mutations.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.